Filing Flows › Prime Medicine (PRME) › Q2 2025
Prime Medicine (PRME) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Prime Medicine (PRME) reported revenue of $1.1M for the second quarter 2025 (Q2 2025) and -23% from the quarter before.
Prime Medicine, Q2 2025: revenue $1.1M, net loss $52.6M, operating cash flow −$41.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | -23% | — |
| Operating profit | −$53.4M | — | — |
| Net earnings | −$52.6M | — | — |
| Operating cash flow | −$41.4M | — | — |
What changed
Revenue was $1.1M in Q2 2025, down 23% from the previous quarter.
Operating costs exceeded revenue by $53.4M, an operating margin of -4787.2%. The quarter ended with a net loss of $52.6M, wider than the previous quarter's $51.9M loss.
Operating cash flow was −$41.4M. Non-cash charges added back $1.9M of depreciation and amortization and $6.3M of share-based compensation. Working capital and other items added $3.0M. Capital expenditures of $1.6M exceeded it, leaving free cash flow of −$43.0M.
Questions
What was Prime Medicine's revenue in the second quarter 2025?
Prime Medicine (PRME) reported revenue of $1.1M for the second quarter 2025 (Q2 2025) and -23% from the quarter before.
Source: Prime Medicine 10-Q on SEC EDGAR.